Last updated on April 2018

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors


Brief description of study

This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely active UC who are naive to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.

Clinical Study Identifier: NCT02165215

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GA29102 ...

Endocare Research
Cape Town, South Africa
1.84miles
  Connect »